Biotech companies seeking to enter biosimilar market

15 February 2012

The Boston Globe (1/20, Weisman) reports, "Bowing to the inevitability of low-cost competition as federal officials push to contain health care spending, biotechs are now scrambling to secure a piece of the discount market for themselves." Momenta Pharmaceuticals Inc., Biogen Idec Inc., and Amgen Inc. "have started separate ventures to develop, make, and market generic biotech drugs, known in the industry as 'biosimilars.'"